ArticleBMC endocrine disorders2026
Predictive value of three insulin resistance surrogate indices for symptomatic hypoglycemia risk in hospitalized patients with type 2 diabetes: a retrospective cohort study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInpatient hypoglycemia is a serious complication in hospitalized patients with type 2 diabetes mellitus (T2DM), associated with adverse outcomes. While insulin resistance (IR) is central to hyperglycemia, its relationship with hypoglycemia risk in acute care settings remains unclear. Convenient IR surrogate indices, such as the triglyceride-glucose index (TyG), triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C), and metabolic syndrome insulin resistance index (METS-IR), warrant evaluation for hypoglycemia prediction.
aimsTo evaluate and compare the predictive utility of three IR indices (TyG, TG/HDL-C, METS-IR) for in-hospital symptomatic hypoglycemia in T2DM patients.
methodsThis retrospective cohort study included 660 hospitalized T2DM patients (April 2024–April 2025) with ≥8-day stay and valid CGM data. Symptomatic hypoglycemia was defined by CGM < 3.9 mmol/L, capillary glucose confirmation, and clinical symptoms. Kaplan-Meier cumulative incidence analysis, multivariable Cox regression, restricted cubic splines, time-dependent ROC, and decision curve analysis were used.
resultsDuring follow-up, 193 (29.2%) patients developed symptomatic hypoglycemia. TyG and METS-IR were inversely associated with symptomatic hypoglycemia risk (per 1-SD increase: HR = 0.680, 95%CI = 0.600–0.773; HR = 0.748, 95%CI = 0.680–0.823), with linear dose-response relationships. TG/HDL-C showed no significant association. TyG exhibited superior model fit (lower AIC), better predictive performance on hospital day 2 (AUC = 0.721), and higher net clinical benefit at 20%–30% risk thresholds. TyG may be more closely linked to symptomatic hypoglycemia risk in patients with good glycemic control, while METS-IR may show a stronger association in those with a longer diabetes duration.
conclusionTyG and METS-IR are valid predictors of in-hospital symptomatic hypoglycemia in T2DM patients. TyG demonstrates optimal predictive performance and clinical utility, supporting its integration into early risk stratification for individualized glycemic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.